The Value Of Peripheral Blood Mononuclear Cell/lymphocyte Ratio In The Prognosis Of Newly Diagnosed Multiple Myeloma Patients Treated With Bortezomib

Objective:To Explore The value of peripheral blood absolute neutrophil/lymphocyte ratio(NLR),absolute monocyte/lymphocyte ratio(MLR),absolute platelet/lymphocyte ratio(PLR)in the prognosis of patients with newly diagnosed multiple myeloma treated with bortezomib.Methods:A retrospective analysis of the clinical data of 81 patients with multiple myeloma(MM)who were treated with bortezomib at the Second Hospital of Shanxi Medical University from January 2011 to January 2018.The NLR,MLR,and PLR thresholds were determined by ROC analysis,and the patients were divided into high value groups(NLR≥ 1.53,MLR ≥ 0.14,PLR ≥ 54.48)and low value groups(NLR < 1.53,MLR < 0.14,PLR < 54.48),and then analyzed the differences in clinical indicators,overall survival(OS)and progression-free survival(PFS)between different NLR,MLR,and PLR groups before treatment.Survival analysis was performed using the Kaplan-Meier method,single factor analysis using Log-rank test,and multivariate analysis using COX regression model.P<0.05 was considered statistically significant.Results:1.Univariate analysis showed that mononuclear cells ≥0.6×109/L,MLR≥0.14,creatinine≥177mmol/L,and DS stage III may be adverse prognostic factors affecting OS;monocytes ≥0.6×109/ L,MLR ≥ 0.14,blood calcium ≥ 2.25 mmol / L,DS stage III may be a poor prognostic factor affecting patients with PFS.2.Multivariate analysis showed that MLR and DS staging were prognostic factors affecting OS and PFS independence.3.Prognosis ratio of different MLR groups in different stages of ISS: The OS comparison results of different MLR groups in ISS stage showed that the OS difference of different MLR groups in ISSIII stage was statistically significant(P=0.021).The PFS comparison of different MLR groups in ISS stages showed that there was a statistically significant difference in PFS between different MLR groups in ISSIII stage(P=0.008).Conclusion:This study showed that peripheral blood MLR is an independent prognostic factor for newly diagnosed MM patients treated with bortezomib,and ISSIII patients are heterogeneous,the prognosis of patients with ISSIII in the high MLR group was poor,and the prognosis in patients with ISSIII in the low MLR group was relatively good.